An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective,
and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.